CLGN vs. COCH, MLSS, RBOT, LFWD, NTRB, INGN, PTWO, IKNA, NVNO, and DERM
Should you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include Envoy Medical (COCH), Milestone Scientific (MLSS), Vicarious Surgical (RBOT), ReWalk Robotics (LFWD), Nutriband (NTRB), Inogen (INGN), Pono Capital Two (PTWO), Ikena Oncology (IKNA), enVVeno Medical (NVNO), and Journey Medical (DERM). These companies are all part of the "medical" sector.
CollPlant Biotechnologies (NASDAQ:CLGN) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.
CollPlant Biotechnologies currently has a consensus price target of $11.00, indicating a potential upside of 65.96%. Envoy Medical has a consensus price target of $6.00, indicating a potential upside of 88.09%. Given Envoy Medical's higher possible upside, analysts clearly believe Envoy Medical is more favorable than CollPlant Biotechnologies.
Envoy Medical has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -64.05%. Envoy Medical's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.
In the previous week, CollPlant Biotechnologies had 2 more articles in the media than Envoy Medical. MarketBeat recorded 4 mentions for CollPlant Biotechnologies and 2 mentions for Envoy Medical. Envoy Medical's average media sentiment score of 1.43 beat CollPlant Biotechnologies' score of 1.23 indicating that Envoy Medical is being referred to more favorably in the news media.
CollPlant Biotechnologies received 130 more outperform votes than Envoy Medical when rated by MarketBeat users. However, 100.00% of users gave Envoy Medical an outperform vote while only 58.59% of users gave CollPlant Biotechnologies an outperform vote.
21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 0.7% of Envoy Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
CollPlant Biotechnologies has higher revenue and earnings than Envoy Medical.
CollPlant Biotechnologies has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500.
Summary
Envoy Medical beats CollPlant Biotechnologies on 8 of the 15 factors compared between the two stocks.
Get CollPlant Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CollPlant Biotechnologies Competitors List
Related Companies and Tools
